Acta Vet. Brno 2024, 93: 305-312
Healing efficacy of a novel wound therapy with enrofloxacin-HCl·2H2O/sodium alginate in unresponsive wounds in dogs
Wound-healing of lesions unresponsive to antibiotic treatment in dogs prompted a clinical trial aimed to assess a new hydrogel based on sodium alginate and the enrofloxacin crystal-solvate (HCl·2H2O [enro-C]). Fifty-six cases of full-thickness infected cavity wounds, unresponsive to at least one complete antibiotic treatment scheme, were included in this trial over a year. Patients were classified into three severity categories based on their lesions’ chronicity and clinical characteristics. The hydrogel was applied twice to four times daily for the necessary time until resolution (endpoint). Follow-up was done every other day for up to 4 weeks when required and weekly for two more months after the endpoint was reached. The hydrogel was internalized in the cavity wounds, delivering the necessary volume which was becoming progressively smaller until healing as perceived by clinicians and owners. A control group was formed based on historical data from the participants’ case filings. All dogs in the trial healed. The mean time needed for full recovery was 6.75 ± 1.36 days in dogs graded severity-1, 13.76 ± 4.2 days for severity-2, and 24.47 ± 6.7 days for severity-3. Tissue concentrations of enro-C/gram of wounded tissue must be determined to improve and rationalize the use of the tested hydrogel, and systemic and topic drug interactions must be determined. The outstanding biocompatibility, gel-forming ability, and lack of apparent toxicity of the hydrogel make it an advantageous option for wound treatment.
Keywords
Funding
This research was partly supported by the Support Program for Research and Technological Innovation Projects (PAPIIT; ID: IT200222), National Autonomous University of Mexico (UNAM). We are grateful to all veterinary clinicians who participated in this trial.
